vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and Investar Holding Corp (ISTR). Click either name above to swap in a different company.
Investar Holding Corp is the larger business by last-quarter revenue ($23.5M vs $21.2M, roughly 1.1× Autolus Therapeutics plc).
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
Investar Holding Corp is a U.S.-headquartered bank holding company that primarily operates across the Gulf Coast region. It delivers a full range of commercial and retail banking services, including deposit products, consumer and business loans, mortgage services, and wealth management solutions for individual clients, small and medium-sized enterprises, and commercial entities.
AUTL vs ISTR — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $23.5M |
| Net Profit | $-79.1M | — |
| Gross Margin | — | — |
| Operating Margin | -337.9% | 30.9% |
| Net Margin | -373.3% | — |
| Revenue YoY | — | 0.9% |
| Net Profit YoY | 3.6% | — |
| EPS (diluted) | $-0.30 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.5M | ||
| Q3 25 | $21.2M | $24.1M | ||
| Q2 25 | $20.9M | $22.3M | ||
| Q1 25 | $9.0M | $24.0M | ||
| Q4 24 | — | $23.3M | ||
| Q3 24 | $0 | $22.3M | ||
| Q2 24 | $0 | $20.4M | ||
| Q1 24 | $10.1M | $21.4M |
| Q4 25 | — | — | ||
| Q3 25 | $-79.1M | $6.2M | ||
| Q2 25 | $-47.9M | $4.5M | ||
| Q1 25 | $-70.2M | $6.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-82.1M | $5.4M | ||
| Q2 24 | $-58.3M | $4.1M | ||
| Q1 24 | $-52.7M | $4.7M |
| Q4 25 | — | 30.9% | ||
| Q3 25 | -337.9% | 31.0% | ||
| Q2 25 | -292.6% | 24.4% | ||
| Q1 25 | -726.3% | 32.2% | ||
| Q4 24 | — | 31.1% | ||
| Q3 24 | — | 27.6% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | -384.1% | 28.5% |
| Q4 25 | — | — | ||
| Q3 25 | -373.3% | 25.6% | ||
| Q2 25 | -229.0% | 20.2% | ||
| Q1 25 | -781.1% | 26.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 24.1% | ||
| Q2 24 | — | 19.9% | ||
| Q1 24 | -522.1% | 22.0% |
| Q4 25 | — | $0.50 | ||
| Q3 25 | $-0.30 | $0.54 | ||
| Q2 25 | $-0.18 | $0.46 | ||
| Q1 25 | $-0.26 | $0.63 | ||
| Q4 24 | — | $0.61 | ||
| Q3 24 | $-0.31 | $0.54 | ||
| Q2 24 | $-0.22 | $0.41 | ||
| Q1 24 | $-0.24 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | — |
| Total DebtLower is stronger | — | $9.8M |
| Stockholders' EquityBook value | $265.5M | $301.1M |
| Total Assets | $661.9M | $2.8B |
| Debt / EquityLower = less leverage | — | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $86.1M | — | ||
| Q2 25 | $123.8M | — | ||
| Q1 25 | $95.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $657.1M | — | ||
| Q2 24 | $705.9M | — | ||
| Q1 24 | $758.5M | — |
| Q4 25 | — | $9.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $9.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $301.1M | ||
| Q3 25 | $265.5M | $295.3M | ||
| Q2 25 | $346.5M | $255.9M | ||
| Q1 25 | $371.1M | $251.7M | ||
| Q4 24 | — | $241.3M | ||
| Q3 24 | $477.0M | $245.5M | ||
| Q2 24 | $527.8M | $230.2M | ||
| Q1 24 | $582.0M | $227.0M |
| Q4 25 | — | $2.8B | ||
| Q3 25 | $661.9M | $2.8B | ||
| Q2 25 | $721.0M | $2.7B | ||
| Q1 25 | $746.3M | $2.7B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | $827.5M | $2.8B | ||
| Q2 24 | $853.6M | $2.8B | ||
| Q1 24 | $901.4M | $2.8B |
| Q4 25 | — | 0.03× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $18.2M |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.2M | ||
| Q3 25 | $-67.9M | $6.9M | ||
| Q2 25 | $-72.8M | $3.2M | ||
| Q1 25 | $-75.6M | $4.5M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | $-76.7M | $5.6M | ||
| Q2 24 | $-51.1M | $2.8M | ||
| Q1 24 | $-40.5M | $7.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-86.3M | — | ||
| Q2 24 | $-51.9M | — | ||
| Q1 24 | $-41.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -406.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 5.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 0.71× | ||
| Q1 25 | — | 0.71× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 1.66× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
